Virtus LifeSci Biotech Clinical Trials ETF
18 hedge funds and large institutions have $3.06M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Holders
18
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.17M | |
| 2 | +$286K | |
| 3 | +$44.4K | |
| 4 |
DI
DAGCO Inc
Westlake,
Ohio
|
+$19.6K |
| 5 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
+$2.86K |
Top Sellers
| 1 | -$46.6K | |
| 2 | -$9K | |
| 3 | -$6.32K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.98K |